breast

Bio & Pharma Volpara to supply breast cancer SW to US Defense Health Agency

Lunit, a South Korean cancer diagnostics AI company, said on Monday its US subsidiary Volpara Health secured a 10 billion won ($7.5 million) contr...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...

Bio & Pharma Volpara to supply cancer diagnostics SW to Intermountain Health

Lunit, a South Korean cancer diagnostics AI company, announced on Wednesday that its subsidiary Volpara Health, a New Zealand-based AI software deve...

Bio & Pharma Lunit to supply AI cancer diagnostics to Qatar

Lunit Inc., a South Korean cancer diagnostics AI company, announced on Monday that it will provide its AI breast cancer screening solution Lunit Ins...

Mergers & Acquisitions Lunit buys breast cancer detection AI firm Volpara Health

Lunit Inc., a South Korean cancer diagnostics AI company, has completed the acquisition of Volpara Health Technologies Ltd., a New Zealand-based AI ...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar

South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...

Bio & Pharma Lunit acquires NZ-based AI diagnostics firm Volpara

South Korean medical AI company Lunit announced on Thursday that it will acquire New Zealand-based AI breast cancer diagnostics solutions company Vo...

Bio & Pharma Celltrion Healthcare's Herzuma selected as funded brand in NZ

Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...

Artificial intelligence Lunit gets FDA approval for AI cancer diagnosis solution

South Korean medical AI company Lunit said on Tuesday its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has...

Bio & Pharma Lunit participates in US gov't Cancer Moonshot

South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moon...

Bio & Pharma Gencurix gets FDA OK for breast cancer prognosis analysis device

South Korean biotech company Gencurix Inc. announced on Wednesday its subsidiary GenoBio has received approval from the US Food and Drug Admini...

Artificial intelligence Lunit to supply AI diagnosis solution to Saudi's medical institution

South Korea's medical AI company Lunit announced on Wednesday that it has signed a contract to supply its artificial intelligence (AI) solution for ...

Bio & Pharma Lunit's Insight DBT gets certification from EU for medical device

South Korean medical AI company Lunit said on Monday that its 3D breast tomosynthesis artificial intelligence (AI) image analysis solution, "Lunit I...

Artificial intelligence S.Korea's Lunit supplies breast cancer imaging solution to UAE

South Korean medical AI company Lunit has supplied its breast cancer imaging analysis solution — Agfa HealthCare Enterprise Imaging — to...

Artificial intelligence Lunit to export breast cancer detecting solutions to Hong Kong, Mongolia

South Korea's AI-based medical imaging equipment firm Lunit will export AI breast cancer diagnosis solutions to large hospitals in Hong Kong and Mon...

Bio & Pharma Celltrion wins sales approval for biosimilar Vegzelma in Japan

Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...